Bernstein analyst Lee Hambright lowered the firm’s price target on Boston Scientific (BSX) to $112 from $130 and keeps an Outperform rating on the shares. The firm notes investors have been worried about intensifying PFA competition, and third-party data stoked anxieties that Boston Scientific could miss in Q4. The company’s CEO tried to calm concerns last month, but alas, Q4 U.S. EP sales of $606M were flat sequentially and missed consensus by 6%, Bernstein says.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific’s (BSX) Earnings Implosion Sparks Bullish Options Trade
- Boston Scientific announces planned board director departure
- Boston Scientific price target lowered to $95 from $120 at Truist
- Boston Scientific price target lowered to $115 from $130 at RBC Capital
- Boston Scientific price target lowered to $97 from $121 at Needham